Neurotech International Ltd
Research Neurotech International Ltd (NTI) on Bullrun: market cap AUD 22.62M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNTI
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 22.62M
- Financial periodFY2025
- RevenueAUD 238
- Revenue growth-87.9%
- Net income-AUD 10.60M
- Free cash flow-AUD 9.02M
- Gross margin100.0%
Valuation Snapshot
latest market cap is AUD 22.62M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | AUD 238 | -AUD 10.60M | -AUD 9.02M | 100.0% | -0.01 | AUD 3.03M | n/a | AUD 2.95M |
| FY2024 | AUD 1.96K | -AUD 5.07M | -AUD 4.60M | -298.9% | -0.01 | AUD 11.63M | n/a | AUD 11.90M |
| FY2023 | AUD 5.96K | -AUD 7.79M | -AUD 6.32M | 100.0% | -0.01 | AUD 5.03M | n/a | AUD 3.96M |
| FY2022 | AUD 38.29K | -AUD 3.36M | -AUD 2.96M | 11.1% | 0 | AUD 1.90M | n/a | AUD 1.43M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | AUD 22.62M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Neurotech International Ltd
Neurotech International Limited, a clinical-stage biopharmaceutical development company, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company focuses on development and commercialization of NTI164 for multiple paediatric neurological disorders; and Mente, a clinically proven home therapy aimed at enhancing engagement and relaxation in autistic children exhibiting elevated delta band brain activity.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Neurotech International Ltd's market cap?
Neurotech International Ltd's market capitalization is AUD 22.62M.
What does Neurotech International Ltd do?
Neurotech International Limited, a clinical-stage biopharmaceutical development company, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company focuses on development and commercialization of NTI164 for multiple paediatric neurological disorders; and Mente, a clinically proven home therapy aimed at enhancing engagement and relaxation in autistic children exhibiting elevated delta band brain activity. It also engages in executing medical research projects; and developing technological devices.